News Apr 2, 2014 FDA grants IND approval for CardioCell’s phase IIa itMSC Therapy trial CardioCell, a global biotechnology company, has just received the FDA’s Investigational New Drug (IND) approval for a U.S.-based, phase IIa clinical study using its allogeneic stem-cell therapy to
Read MoreFDA Gives Go-Ahead for Phase 2a Trial of CardioCell CHF Stem Cell Therapy
News Apr 2, 2014 FFDA Gives Go-Ahead for Phase 2a Trial of CardioCell CHF Stem Cell Therapy CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based, Phase 2a clinical study using its allogeneic stem-cell therapy to treat subjects
Read MoreCardioCell gets IND approval from FDA
News Apr 2, 2014 CardioCell gets IND approval from FDA San Diego-based CardioCell LLC on Wednesday received the Food and Drug Administration’s investigational new drug (IND) approval for a phase 2a clinical study using its allogeneic stem-cell therapy to treat subjects with chronic
Read MoreFDA Grants IND Approval For Phase 2a Clinical Trial Using CardioCell’s Itmsc Therapy To Treat Dilated Chronic Heart Failure
News Apr 2, 2014 FDA Grants IND Approval For Phase 2a Clinical Trial Using CardioCell’s Itmsc Therapy To Treat Dilated Chronic Heart Failure CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using
Read MoreFDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell’s itMSC Therapy to Treat Dilated Chronic Heart Failure
News Apr 2, 2014 FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell’s itMSC Therapy to Treat Dilated Chronic Heart Failure SAN DIEGO — April 2, 2014 — CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based,
Read More